http://orcid.org/0000-0001-7192-4305
References
- Du M, Chase M, Oguz M, Davies G. et al. State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. CMRO, Article in press, 12 Mar 2017. http://dx.doi.org/10.1080/03007995.2017.1301902
- Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33
- Zontivity. Full prescribing information. FDA Label. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ucm423935.htm [Last accessed 29 May 2017]
- Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 2012;68:249-58
- Kosoglou T, Reyderman L, Tseng J, et al. Effect of food, antacid, and age on the pharmacokinetics of the oral thrombin receptor antagonist vorapaxar (SCH 530348) in healthy volunteers. Clin Pharmacol Drug Dev 2013;2:223-30
- Ghosal A, Lu X, Penner N, Gao L, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 2011;39:30-8
- Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. J Clin Pharmacol 2013;53:540-9
- Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13
- Bonaca MP, Creager MA, Olin J, et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2 degrees P–TIMI 50 Trial. JACC Cardiovasc Interv 2016;9:2157-64
- Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P-TIMI 50). Circulation 2016;133:997-1005
- Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events–TIMI 50 trial. Circulation 2015;131:1047-53
- Eisen A, Bonaca MP, Jarolim P, et al. High-sensitivity troponin I in stable patients with atherosclerotic disease in the TRA 2 degrees P–TIMI 50 Trial. Clin Chem 2017;63:307-15
- Sharma A, Helft G, Garg A, et al. Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: a meta-analysis of randomized control trials. Int J Cardiol 2017;227:617-24
- Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 2016;134:304-13
- Serebruany VL, Fortmann SD, Kim MH. Vorapaxar and optimal aspirin dose: the FDA outlook. Int J Cardiol 2016;203:903-5